Reuters -- Sharply higher sales of flu drug Relenza buoyed GlaxoSmithKline’s (GSK.L) quarterly sales and the British group said it was in line for a big swine flu vaccine boost in the last three months of the year.
Reuters -- Sharply higher sales of flu drug Relenza buoyed GlaxoSmithKline’s (GSK.L) quarterly sales and the British group said it was in line for a big swine flu vaccine boost in the last three months of the year.
